Halozyme Therapeutics | HALO - Stock


Halozyme Therapeutics reported $176.48M in Stock for its fiscal quarter ending in December of 2025.





Stock Change Date
Acadia Pharmaceuticals USD 34.67M 5.57M Dec/2025
Agios Pharmaceuticals USD 32.92M 886K Dec/2025
Alnylam Pharmaceuticals USD 82.72M 7.34M Dec/2025
Amarin USD 184.7M 13.46M Sep/2025
Amgen USD 6.22B 121M Dec/2025
Baxter International USD 2.23B 228M Dec/2025
Cara Therapeutics USD 900K 0 Mar/2025
Cytokinetics USD 0 0 Dec/2023
Eli Lilly USD 13.74B 1.56B Dec/2025
Esperion Therapeutics USD 108.54M 5.93M Sep/2025
Halozyme Therapeutics USD 176.48M 9.32M Dec/2025
Intrexon USD 287K 68K Dec/2022
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
MannKind USD 35.31M 8.34M Dec/2025
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Pfizer USD 11.47B 201M Sep/2025
Rigel Pharmaceuticals USD 13.3M 2.88M Sep/2025
United Therapeutics USD 183.1M 6.6M Dec/2025
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025